# Cipla Limited - Inspection Records Source: https://www.keypedia.com/companies/cipla-limited/6b5864ed-07a2-4861-b424-021018d4f7e9 > Inspection records and compliance data for Cipla Limited in Goa, None. Access full analysis and detailed observations. --- ## Details - Name: Cipla Limited - FEI Number: 3004081307 - City: Goa - State: None - Country Name: India - Address Line 1: L129 - 146 S - 103 - 105 S - 107 - 112 L147 - L147 1 - Address Line 2: Vasco Da Gama - Zip Code: None - Facility Type: Drug Manufacturer - Business Operations: FDF MANUFACTURE ## Related Documents - [483 - Cipla Limited - 2026-04-17](https://www.keypedia.com/records/483/cipla-limited/f93aa02d-a913-4889-8748-02bf348c39b6) — source: FDA, date: April 17, 2026 - [FDA Inspection 1313374 - Cipla Limited - 2026-04-17](https://www.keypedia.com/records/fda_inspections/cipla-limited/489043bc-019c-4418-931e-6518183cfd6b) — source: FDA, date: April 17, 2026 - [FDA Inspection 1313374 - Cipla Limited - 2026-04-17](https://www.keypedia.com/records/fda_inspections/cipla-limited/47decda4-77f8-4163-ab2d-e0cd8c50e259) — source: FDA, date: April 17, 2026 - [483 - Cipla Limited - 2024-06-21](https://www.keypedia.com/records/483/cipla-limited/8db1e1bc-0bc5-4334-9558-e7aa003c3b7d) — source: FDA, date: June 21, 2024 - [483 - Cipla Limited - 2024-06-21](https://www.keypedia.com/records/483/cipla-limited/6e6db655-6ac9-49bd-9d30-2442d2bf857f) — source: FDA, date: June 21, 2024 - [FDA Inspection 1240813 - Cipla Limited - 2024-06-21](https://www.keypedia.com/records/fda_inspections/cipla-limited/8bbdb860-88af-47ff-ac3a-04cb8bedbcad) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 21, 2024 - [483 - Cipla Limited - 2022-08-26](https://www.keypedia.com/records/483/cipla-limited/3c4414ab-af3a-425d-bb60-2b91ddd03159) — source: FDA, date: August 26, 2022 - [483 - Cipla Limited - 2022-08-26](https://www.keypedia.com/records/483/cipla-limited/4847f9f1-e066-460e-aa6f-a79ada9678a4) — source: FDA, date: August 26, 2022 - [FDA Inspection 1178952 - Cipla Limited - 2022-08-26](https://www.keypedia.com/records/fda_inspections/cipla-limited/dc52b0e2-2947-4e2d-9bdf-1a9dc7fb515e) — classification: Official Action Indicated (OAI), source: FDA, date: August 26, 2022 - [483 - Cipla Limited - 2019-09-27](https://www.keypedia.com/records/483/cipla-limited/df1fd743-d55e-4cd8-aa93-f66bb318c12d) — source: FDA, date: September 27, 2019 - [483 - Cipla Limited - 2019-09-27](https://www.keypedia.com/records/483/cipla-limited/6ab9733d-f9eb-40af-874b-7ca1a2214662) — source: FDA, date: September 27, 2019 - [FDA Inspection 1103305 - Cipla Limited - 2019-09-27](https://www.keypedia.com/records/fda_inspections/cipla-limited/3d4ad184-ec01-4b07-8d4c-c5a5edc56a1a) — classification: Official Action Indicated (OAI), source: FDA, date: September 27, 2019 - [FDA Inspection 1103305 - Cipla Limited - 2019-09-27](https://www.keypedia.com/records/fda_inspections/cipla-limited/8e4dda74-73d5-4f2e-853a-19cf3d2511d5) — classification: Official Action Indicated (OAI), source: FDA, date: September 27, 2019 - [EIR - Cipla Limited - 2019-01-28](https://www.keypedia.com/records/eir/cipla-limited/a706c6c3-0594-4c74-9fdc-cad98c532f4e) — source: FDA, date: January 28, 2019 - [483 - Cipla Limited - 2019-01-28](https://www.keypedia.com/records/483/cipla-limited/96151c31-a5c8-4cfa-b564-ee38cfa14dad) — source: FDA, date: January 28, 2019 - [FDA Inspection 1078911 - Cipla Limited - 2019-01-28](https://www.keypedia.com/records/fda_inspections/cipla-limited/f442d154-0a0c-46ea-ba3d-7b670aa57332) — classification: Voluntary Action Indicated (VAI), source: FDA, date: January 28, 2019 - [FDA Inspection 1078911 - Cipla Limited - 2019-01-28](https://www.keypedia.com/records/fda_inspections/cipla-limited/40022821-c763-46fa-bc75-58ecaf478d52) — classification: Voluntary Action Indicated (VAI), source: FDA, date: January 28, 2019 - [483 - Cipla Limited - 2018-09-28](https://www.keypedia.com/records/483/cipla-limited/19271680-9b57-470b-88a8-053b854fc6d1) — source: FDA, date: September 28, 2018 - [FDA Inspection 1069950 - Cipla Limited - 2018-09-28](https://www.keypedia.com/records/fda_inspections/cipla-limited/fd66a0e6-fa12-4219-bb1a-572cd01b3c0f) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 28, 2018 - [FDA Inspection 1015874 - Cipla Limited - 2017-06-16](https://www.keypedia.com/records/fda_inspections/cipla-limited/0671a700-583b-47a7-8a57-ffe202f53df4) — classification: No Action Indicated (NAI), source: FDA, date: June 16, 2017 ## Related Companies - [Rechon Life Science AB](https://www.keypedia.com/companies/rechon-life-science-ab/ce84eed4-ada6-40a0-9005-2c2d6bbd729d) - [Nephron Sc Inc](https://www.keypedia.com/companies/nephron-sc-inc/2dadfd52-37b7-4da6-9885-864d470c1b18) - [Glenmark Pharmaceuticals Limited](https://www.keypedia.com/companies/glenmark-pharmaceuticals-limited/8a329d32-4a7d-4062-8336-1a4c9455759e) - [Dendreon Pharmaceuticals LLC](https://www.keypedia.com/companies/dendreon-pharmaceuticals-llc/68ccd67e-0a3a-41cb-ae30-e9e10a6eaef5) - [Modavar Pharmaceuticals](https://www.keypedia.com/companies/modavar-pharmaceuticals/9b63702d-7db4-4738-8b79-5f7fc9cd73d6) - [Celltrion Pharm, Inc.](https://www.keypedia.com/companies/celltrion-pharm-inc/481a4273-bf7e-4b37-8cd8-08b977ba576b) - [GRANULES LIFE SCIENCES PRIVATE LIMITED](https://www.keypedia.com/companies/granules-life-sciences-private-limited/434955b0-03c5-4fc0-a6c2-1241872c2974) - [Procter & Gamble Manufactura S. de R.L. de C.V.](https://www.keypedia.com/companies/procter-gamble-manufactura-s-de-rl-de-cv/8b78eeab-6efe-4a8d-b98a-c1bfda966646) - [TOLMAR, Inc.](https://www.keypedia.com/companies/tolmar-inc/a73dea00-baea-4f0e-8234-c0becc61322e) - [Qilu Animal Health Products Co., Ltd.](https://www.keypedia.com/companies/qilu-animal-health-products-co-ltd/8466eb41-9765-42fd-bcb9-1967ddab39db) ## Related Officers - [Cheryl A. Clausen](https://www.keypedia.com/people/cheryl-a-clausen/2306b2bc-8f01-4f77-ba2d-1a3186d6f6fc) - [Branch Chief, Foreign Pharmaceutical Quality Inspection at FDA](https://www.keypedia.com/people/kevin-a-gonzalez/3f0a5230-3804-4df2-9a5e-3ea805ba9b79) - [Consumer Safety Officer](https://www.keypedia.com/people/rajiv-r-srivastava/05b42bfd-0cf4-42ce-89e1-b81bf36eaa17) - [Thomas J. Arista](https://www.keypedia.com/people/thomas-j-arista/37905892-3285-4f3f-b4b5-f963df1e59d3) - [Regional Manager](https://www.keypedia.com/people/jonah-s-ufferfilge/6bcd2028-9aca-4704-bd7b-c835874fad9d) - [Teresa I. Navas](https://www.keypedia.com/people/teresa-i-navas/43f747c0-18c2-4630-bab9-936204aa93aa)